Brief: Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer In Single-Region Trial Conducted By Akeso In China
25/08/2026 23:01
BRIEF-Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer In Single-Region Trial Conducted By Akeso In China Aug 25 (Reuters) - Summit Therapeutics Inc. SMMT.O:
IVONESCIMAB PLUS CHEMOTHERAPY DEMONSTRATES STATISTICALLY SIGNIFICANT OVERALL SURVIVAL BENEFIT COMPARED TO DURVALUMAB PLUS CHEMOTHERAPY IN FIRST-LINE ADVANCED BILIARY TRACT CANCER IN SINGLE-REGION TRIAL CONDUCTED BY AKESO IN CHINA
SUMMIT THERAPEUTICS - STUDY MEETS KEY SECONDARY ENDPOINTS OF PFS AND ORR
Source text: ID:nBwbBrqNa
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)